J Biol Chem, Vol. 274, Issue 40, 28087-28095, October 1, 1999
Protein Kinase B Stimulates the Translocation of GLUT4 but Not
GLUT1 or Transferrin Receptors in 3T3-L1 Adipocytes by a Pathway
Involving SNAP-23, Synaptobrevin-2, and/or Cellubrevin*
Patrick G. P.
Foran
,
Laura M.
Fletcher§,
Paru B.
Oatey§,
Nadiem
Mohammed
,
J. Oliver
Dolly
, and
Jeremy M.
Tavaré§¶
From the
Department of Biochemistry, Imperial
College, London SW7 2AY and the § Department of
Biochemistry, School of Medical Sciences, University of Bristol,
Bristol, BS8 1TD United Kingdom
 |
ABSTRACT |
An interaction of SNAP-23 and syntaxin 4 on the
plasma membrane with vesicle-associated synaptobrevin-2 and/or
cellubrevin, known as SNAP (soluble
N-ethyl-maleimide-sensitive factor attachment protein) receptors or SNAREs, has
been proposed to provide the targeting and/or fusion apparatus for
insulin-stimulated translocation of the GLUT4 isoform of glucose
transporter to the plasma membrane. By microinjecting 3T3-L1 adipocytes
with the Clostridium botulinum toxin B or E, which
proteolyzed synaptobrevin-2/cellubrevin and SNAP-23, respectively, we
investigated the role of these SNAREs in GLUT4, GLUT1, and transferrin
receptor trafficking. As expected, insulin stimulated the translocation
of GLUT4, GLUT1, and transferrin receptors to the plasma membrane. By
contrast, a constitutively active protein kinase B (PKB-DD) only
stimulated a translocation of GLUT4 and not GLUT1 or the transferrin
receptor. The GLUT4 response to PKB-DD was abolished by toxins B or E,
whereas the insulin-evoked translocation of GLUT4 was inhibited by
approximately 65%. These toxins had no significant effect on
insulin-stimulated transferrin receptor appearance at the cell surface.
Thus, insulin appears to induce GLUT4 translocation via two distinct
routes, only one of which involves SNAP-23 and
synaptobrevin-2/cellubrevin, and can be mobilized by PKB-DD. The PKB-,
SNAP-23-, and synaptobrevin-2/cellubrevin-independent GLUT4
translocation pathway may involve movement through recycling endosomes,
together with GLUT1 and transferrin receptors.
 |
INTRODUCTION |
In muscle, adipose tissue, and 3T3-L1 adipocytes, insulin
primarily increases glucose uptake by promoting the trafficking of
vesicles containing GLUT4 (glucose transporter
isoform 4) to the plasma membrane (reviewed in Refs. 1 and
2). In the resting state, the majority of GLUT4 resides in vesicles
distributed throughout the cell interior, with a fraction of GLUT4
undergoing cycling between the plasma membrane and several
intracellular sorting compartments. Insulin triggers a substantial
translocation of GLUT4-containing vesicles to the plasma membrane, a
phenomenon that can largely explain the increase in
Vmax of the glucose uptake observed. A detailed
molecular description of how insulin promotes this translocation is
presently lacking, although some of the components involved in the
signaling process and the fusion events have been identified.
Binding of insulin to its receptor activates the integral tyrosine
kinase, which then elicits a cascade of cellular signaling responses,
including phosphorylation of the cytosolic proteins of the
insulin-receptor-substrate family (reviewed in Ref. 3). As a
consequence of tyrosine phosphorylation, insulin-receptor substrates-1
and -2 bind several effectors; the resultant activation of
phosphatidylinositide (4,5)-bisphosphate kinase
(PI3-kinase)1 is of
particular importance because it is known to play a key role in
transducing the insulin signal leading to GLUT4 vesicle translocation
(4-6). The lipid product of this enzyme, namely phosphatidylinositide
3,4,5-trisphosphate, promotes the phosphorylation and activation of the
serine/threonine-kinase called protein kinase B (PKB; also known as RAC
or Akt) via two protein kinases named PDK1 and PDK2 (7).
Overexpression of constitutively active forms of PKB causes increased
glucose uptake and GLUT4 translocation in adipocytes in the absence of
insulin (8, 9), suggesting that this protein kinase may also be a
crucial mediator of the effect of insulin on glucose transport, at
least in part.
The molecular mechanism of GLUT4 vesicle fusion with the plasma
membrane appears to share considerable similarity with
Ca2+-evoked exocytosis in neurons and neuroendocrine cells
(reviewed in Ref. 10). In neurons, Söllner and co-workers (11)
have proposed that the core of the synaptic-clear vesicle
docking/fusion complex comprises two plasma membrane proteins, syntaxin
1 and SNAP-25 (synaptosomal protein with a molecular mass
of 25 kDa), which interact with synaptobrevin (Sbr) on the
vesicle. This provides the targeting specificity and/or the fusion
apparatus necessary for neurotransmitter release at the active zones of
nerve endings. Additionally, these three proteins serve as receptors
for the cytosolic factors N-ethyl-maleimide-sensitive factor
and SNAP (soluble
N-ethyl-maleimide-sensitive factor
attachment protein), which collectively
regulate the ternary associations and, therefore, are referred to as
SNAREs (SNAP receptors). SNAP-25 and syntaxin
1, located predominantly on the targeted plasma membrane, are referred
to as t-SNAREs, whereas vesicle located Sbr is the v-SNARE (11). An
involvement of Sbr-2 and/or its ubiquitous non-neuronal homologue, Cbr
(12), and syntaxin 4 (13) in insulin-stimulated GLUT4 vesicle fusion in
3T3-L1 adipocytes has been demonstrated. Their appropriate subcellular
locations and protein associations support such a role (14-21); also,
the process is inhibited by the cytosolic delivery of selective
antibodies against syntaxin 4 (14) and overexpression of interfering
SNARE mutants (16, 22). Recently, Martin and co-workers (23)
demonstrated that introduction of Sbr-2, but not Sbr-1 or Cbr proteins,
into these cells could block insulin-stimulated translocation.
Moreover, botulinum neurotoxin (BoNT) serotypes B and D or tetanus
toxins (TeTx), which selectively proteolyze Sbr isoforms and Cbr (see below), have been instrumental in establishing the involvement of these
v-SNAREs in insulin-induced glucose uptake and GLUT4 trafficking (21,
24-26).
TeTx and serotypes A to G of BoNT are similar but immunologically
distinct proteins produced by Clostridium tetani and
Clostridium botulinum, respectively. They are composed of a
heavy chain and light chain linked by a disulphide bond and noncovalent
interactions. The heavy chain is responsible for high affinity binding
to neuronal cholinergic ecto-acceptors, subsequent internalization, and
translocation of the active moiety into the cytosol, where the light
chain blocks exocytosis (reviewed in Refs. 27-30). The light chains of
BoNTs and TeTx are Zn2+-dependent endoproteases
(reviewed in Refs. 28-30). Sbr is proteolyzed by TeTx and BoNT/B,/D,/F
and/G (reviewed in Refs. 28-30); Cbr is also cleaved by TeTx and
BoNT/B (12, 31). BoNT/A and/E proteolyze SNAP-25 at separate
C-terminally located sites, whereas BoNT/C1 cleaves both syntaxin 1 (reviewed in Refs. 28-30) and SNAP-25 (32, 33).
Using highly sensitive Western blotting methods, we (21) and others
(18, 20, 25, 34, 35) have been unable to detect any SNAP-25 in 3T3-L1
adipocytes. This led to the suggestion that the recently cloned (from
human (36) and mouse (37, 38)), non-neuronal homologue termed SNAP-23
(also referred to as Syndet), which is found at high levels and at the
appropriate plasma membrane location in 3T3-L1 adipocytes (21, 37, 38),
may substitute for SNAP-25 to provide the high affinity ternary
docking/fusion complex described (39, 40). The association of SNAP-23
with Sbr-2/Cbr and syntaxin isoforms demonstrated in vitro
(36, 37, 41) is consistent with a potential role of SNAP-23 in the
fusion between GLUT4 vesicles and the plasma membrane. Indeed,
recently, Rea and colleagues (42) have demonstrated that
insulin-stimulated GLUT4 translocation to the plasma membrane was
partially blocked upon the introduction into 3T3-L1 adipocytes of
either anti-SNAP-23 antibodies or a synthetic peptide corresponding to
the last 24 C-terminal amino acids of SNAP-23.
In this study we have investigated the mechanism by which insulin and a
constitutively active PKB (PKB-DD) induce the translocation of GLUT4 to
the plasma membrane of 3T3-L1 adipocytes. BoNT/B and BoNT/E, which
specifically cleave Sbr-2/Cbr and SNAP-23, respectively, completely
blocked the effect of PKB-DD but only partially blocked the effect of
insulin. We also found that insulin, but not PKB-DD, caused GLUT1 and
TfR translocation, in a manner that was insensitive to the actions of
BoNT/B and/E. Collectively, our results support the hypothesis (16, 23,
42, 43) that insulin may operate via two distinct pathways to promote
GLUT4 vesicle fusion with the plasma membrane. In addition, our data
suggest that only one of these trafficking pathways can be mobilized by
a constitutively active PKB.
 |
EXPERIMENTAL PROCEDURES |
Materials--
A murine 3T3-L1 fibroblast clone (obtained from
ATCC; number CCL 92.1) was supplied by the European Collection of
Animal Cell Cultures (Salisbury, UK). Tissue culture reagents were from
Life Technologies, Inc. or Sigma. High purity digitonin was purchased from Novabiochem (town, UK). Affinity-isolated anti-species-specific Ig
conjugated with horseradish peroxidase, insulin and all other reagents
were obtained from Sigma. Rabbit anti-GLUT1 antibodies were a gift of
Dr. S. Baldwin (University of Leeds). A monoclonal antibody specific
for human transferrin receptor (hTfR) was provided by Dr. C. Holmes
(University of Bristol), and a plasmid (pCMV5·hTfR) encoding the hTfR
cDNA under the control of the cytomegalovirus promoter was kindly
provided by Dr. H. Mellor (University of Bristol). The plasmid
pGFP-GLUT4 has been described elsewhere (44). The pCMV5 vector was also
used to overexpress wild-type and constitutively active (-DD;
containing substitutions of Thr308 and Ser473
for aspartic acid residues) forms of PKB (45), and were kindly provided
by Drs. Brian Hemmings (Friedrich Miescher Institute, Basel) and Dario
Alessi (University of Dundee).
Antibodies were raised in rabbits against a soluble recombinant
His6-tagged form of mouse syntaxin 1A, lacking the last 27 C-terminal residues, and were affinity-purified on the immobilized antigen (32). Affinity-purified Ig raised against residues 33-94 of
human Sbr-2 (a region of amino acid sequence shared with Sbr and Cbr;
Ref. 12) was prepared, as detailed elsewhere (32). Because only poor
sequence identities exist between Sbr-2/VAMP-2 and the other recently
identified mammalian VAMP isoforms 4-8 (46), their immunoreactivity
with this antibody is not expected. Moreover, VAMP isoforms 4-8 are
unlikely to be proteolyzed by BoNT/B because of their sequence
diversites (47). Likewise, a rabbit antiserum to the C terminus of
SNAP-25 (residues 195-206) was produced and affinity-purified (48).
Antisera were generated in rabbits against peptides corresponding to
the C-terminal 11 residues of human SNAP-23 (ANARAKKLIDS); specific Ig
was affinity-isolated from immune sera using the immunogenic peptide
coupled via its additional N-terminal cysteine to iodoacetyl-Sepharose
4B (prepared as detailed in Ref. 48). Each affinity-purified Ig was
tested to ensure that it labeled the requisite protein of appropriate Mr on Western blots in a manner that was
preventable by inclusion of the immunogen (data not shown).
Isolated BoNT/A, BoNT/B, BoNT/C1, and BoNT/E were purified and fully
nicked, where necessary, as described previously (21, 48, 49); all were
shown to be of high purity by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis with Coomassie staining of protein and found to exhibit
the high levels of toxicity (assessed by mouse bioassay) as published.
Permeabilization of Cells with Digitonin to Observe the
Proteolytic Activities of BoNT/A, BoNT/B,
BoNT/C1, or BoNT/E--
Bovine chromaffin cells
were prepared from adrenal glands and maintained in culture, as
detailed elsewhere (50). Differentiated 3T3-L1 adipocytes were prepared
as outlined before (21). Cells (0.5 × 106 cells/well)
were washed three times with buffer A (136 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM CaCl2, 1.2 mM
NaH2PO4, 5 mM NaHCO3, 10 mM HEPES, pH 7.4). They were then permeabilized at
37 °C using 40 µM digitonin in KGEP buffer (139 mM K+ glutamate, 20 mM PIPES-HCl,
pH 7.0, 1 mM EGTA, 2 mM MgCl2, 2 mM ATP, 0.25 mM phenylmethylsulfonyl fluoride,
20 µg/ml leupeptin, and 10 µg/ml pepstatin A) in the absence or
presence of prereduced BoNT/A, BoNT/B, BoNT/C1, or BoNT/E (at the
concentrations given in the figure legends). More than 95% of the
cells (of the three different lines employed) exhibited nuclear
staining by trypan blue, confirming the efficacy of permeabilization.
BoNTs were reduced with 20 mM dithiothreitol in 25 mM HEPES, pH 7.4, containing 0.15 M NaCl for a
minimum of 30 min at 37 °C before dilution in digitonin-KGEP and
application to cells; neurotoxin-free control cells were exposed to the
same final concentration of dithiothreitol, which never exceeded 1 mM. After incubation, the medium was aspirated and replaced
with 50 mM NaHCO3, pH 8.5, containing protease
inhibitors and the cells were harvested and homogenized (detailed in
Ref. 31). The homogenate was adjusted to 0.32 M
sucrose and centrifuged at 800 × g for 10 min, and the
resultant supernatant was subjected to 390,000 × g for
1 h to sediment all remaining membranes. The resultant pellets
were solubilized in 100 mM Tris, pH 6.8, containing 2%
(w/v) SDS plus 1 mM EDTA and solubilized by heating to
90 °C for 10 min.
Immunoblotting and Quantitation of Antigens--
Samples were
subjected to immunoblotting as detailed in Ref. 21. Antibodies bound to
the membranes were detected with anti-species-specific Ig conjugated to
horseradish peroxidase and visualized by enhanced chemiluminescence,
using the ECLTM detection system (Amersham Pharmacia
Biotech). The blots were quantified by densitometric scanning, using
image analysis software (National Institutes of Health Image version
1.61), and the resultant values were expressed as a percentage of the
toxin-free control. In addition, standard curves of the various amounts
of SNARE proteins plotted against band intensity were found to be linear.
Cell Culture, Adipocyte Differentiation, and
Microinjection--
3T3-L1 fibroblasts were grown on polylysine-coated
glass coverslips, and once the adipocyte phenotype was attained (using procedures detailed in Ref. 44), they were equilibrated in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) myoclone plus fetal calf serum, 25 mM HEPES, pH 7.4, and 2 mM
NaHCO3, and microinjected using an Eppendorf semi-automatic
system. Plasmids were microinjected at 20-100 µg/ml in the absence
or presence of prereduced BoNT/B (2 µM) or BoNT/E (1 µM) in 10 mM HEPES, pH 7.5, containing 2 mM MgCl2, 10 mM dithiothreitol, and
50 µM ZnSO4. It is estimated that
approximately 10% of the cell volume is delivered during microinjection, thus providing an intracellular concentration of toxin
of 100-200 nM. After microinjection, the cells were
incubated at 37 °C in Dulbecco's modified Eagle's medium
containing 10% (v/v) myoclone plus fetal calf serum for 16-24 h.
Before further manipulation, adipocytes were incubated for 2 h at
37 °C in serum-free Dulbecco's modified Eagle's medium and then
for 1 h in the presence of 200 nM insulin, as required.
Immunofluorescence Analysis--
In some experiments, the
cellular distribution of expressed PKB (which possesses a HA tag) was
determined. Cells were fixed and permeabilized, using 4%
paraformaldehyde and 1% Triton X-100. Unless otherwise stated, all
subsequent steps were performed in phosphate-buffered saline
supplemented with 3% bovine serum albumin. In some experiments, the
cells were stained with monoclonal anti-HA antibodies (10 µg/ml of
HA11; Berkeley Antibody Company, CA) for 30 min, followed by incubation
in a 1:200 dilution of fluorescein isothiocyanate-conjugated goat
anti-mouse IgG (Sigma) or TRITC-conjugated rabbit anti-mouse IgG (Dako
Laboratories) for 30 min. In other experiments, PKB was visualized
using a 1:200 dilution of a rabbit polyclonal anti-HA antiserum (Santa
Cruz) followed by incubation in 1:200 dilution of TRITC-conjugated goat
anti-rabbit IgG (Sigma) for 30 min.
To detect the insulin-responsive aminopeptidase, IRAP, the fixed and
permeabilized cells were stained with a rabbit polyclonal anti-IRAP
serum (5 µg/ml; a kind gift of Drs. Susanna Keller and Gus Lienhard)
in phosphate-buffered saline with 3% bovine serum albumin for 30 min.
This was followed by a 1:200 dilution of TRITC-conjugated goat
anti-rabbit IgG for 15 min. GLUT1 was immunostained using the same
procedure but with 25 µg/ml rabbit anti-GLUT1 antibody for 1 h
followed by a 1:200 dilution of TRITC-conjugated goat anti-rabbit IgG
for 30 min.
Transferrin receptors were detected by staining fixed cells with
undiluted monoclonal anti-transferrin receptor hybridoma supernatant in
phosphate-buffered saline. Depending on the nature of the experiment,
this was followed by a 1:200 dilution of TRITC-conjugated rabbit
anti-mouse IgG or fluorescein isothiocyanate-conjugated goat anti-mouse
IgG (Sigma) for 30 min in phosphate-buffered saline with 3% bovine
serum albumin.
Confocal Microscopy and Image Analysis--
Confocal microscopy
was performed with a Leica DM IRBE inverted confocal microscope
controlled with TCS-NT4 software (Leica). Images were processed with
Adobe Photoshop 3.0 and Freelance Graphics 95 (Lotus). The extent of
GFP-GLUT4 translocation to the plasma membrane was quantified by
marking a region of interest around the exterior and interior faces of
the plasma membrane in the confocal image. The levels of fluorescence
intensity within these areas were then computed using TCS-NT software,
and the intensity of plasma membrane localized GFP-GLUT4 fluorescence
(FPM) expressed as a percentage of total
cellular GFP-GLUT4 fluorescence intensity (FT).
This method corrects for variations in cell shape, size, and the
expression level of GFP-GLUT4.
 |
RESULTS |
Murine, but Not Human, SNAP-23 Is Proteolyzed by BoNT/E--
To
investigate the role of SNAP-23 in GLUT4 vesicle docking and fusion
with the adipocyte plasma membrane, the susceptibilities of the murine
and human isoforms to proteolytic attack by BoNT/E were examined. A
digitonin-based permeabilization method was used to introduce the toxin
into cells, because it is known to allow efficient cleavage of other
SNAREs (outlined in Ref. 21). Following incubation in the absence or
presence of BoNTs, permeabilized cells were lysed and subjected to
immunoblotting using primary antibodies reactive with the relevant
SNAREs (detailed in "Experimental Procedures"). Indeed, application
of BoNT/A, BoNT/C1, or BoNT/E to permeabilized bovine chromaffin cells
resulted in cleavage of the majority of SNAP-25, type C1, additionally,
proteolyzed syntaxin 1, whereas BoNT/B proteolyzed the Sbr isoforms and
Cbr present (Fig. 1). Also, BoNT/B gave
nearly complete cleavage of Cbr and Sbr in permeabilized mouse 3T3-L1
adipocytes and human CACO-2 cells (Fig. 1). These data confirm the high
proteolytic activities and appropriate substrate selectivities of the
BoNT serotypes used in this study.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 1.
Proteolysis of murine SNAP-23 but not the
human isoform by BoNT E. Bovine adrenomedullary chromaffin cells,
3T3-L1 adipocytes, or human CACO-2 cells were incubated with
digitonin-KGEP permeabilization buffer at 37 °C for 30 min in the
absence or presence of 100 nM of the specified prereduced
BoNT serotype. A total membrane fraction was prepared, and equal
amounts of protein (20 µg for chromaffin cells and 50 µg for 3T3-L1
or CACO-2 cells) were immunoblotted using the antibodies indicated.
Binding of primary antibodies was detected with horseradish
peroxidase-conjugated secondary antibodies and visualized using
enhanced chemiluminescence (see "Experimental Procedures").
|
|
The cleavage of SNAP-23 at its C terminus by BoNT/E was investigated
using an antiserum that recognizes the C-terminal 11 amino acids
downstream of the putative cleavage site in murine SNAP-23 (potentially
between Lys185-Ile186 (21)); the expectation
was that this cleavage would result in the disappearance of its
immunoreactivity on Western blots. Whereas treatment of permeabilized
mouse and human cells for 30 min with 100 nM of either
BoNT/A or BoNT/C1 failed to produce significant cleavage of either
murine or human SNAP-23, an identical exposure to BoNT/E diminished the
level of reactivity of murine SNAP-23 (Fig. 1). Quantitation by
densitometric scanning revealed that BoNT/E removed 76.8 ± 2.9%
(mean ± S.D from four separate experiments) of the immunoreactive
SNAP-23 present, compared with toxin-free control. In contrast to this
extensive cleavage of murine SNAP-23, BoNT/E consistently failed to
yield detectable proteolysis of SNAP-23 in the human CACO-2 cell line,
under the same conditions (Fig. 1); however, a very slow rate of
cleavage cannot be excluded. Furthermore, BoNT/E did not alter the
abundance of Sbr-2/Cbr or syntaxin isoforms 1 or 4 in any of these cell lines, reaffirming its known selective proteolytic action (Fig. 1). The
observed insensitivity of syntaxin 4 to proteolytic attack by type C1
(Fig. 1) confirms earlier studies (51).
A Requirement for Zn2+ and Prereduction of the
Interchain Disulphide of BoNT/E for Proteolysis of Murine SNAP-23
Establishes Its Selective Action--
To reliably confirm that murine
SNAP-23 is cleaved by BoNT/E, we investigated two physical requirements
for the proteolytic activities of the other BoNT serotypes shared by
type E, namely that Zn2+ is essential and that reduction of
the interchain disulphide bridge is necessary to activate the protease
of the light chain (reviewed in Refs. 28-30). As shown in Fig.
2, prereduction of BoNT/E was found to be
a prerequisite for proteolysis of SNAP-23 in permeabilized 3T3-L1
adipocytes. Moreover, incubation of reduced BoNT/E with the divalent
cation chelators EDTA, dipicolinic acid, and 1,10-phenanthroline (which
is highly selective for Zn2+, compared with
Ca2+ or Mg2+) before introduction into 3T3-L1
adipocytes removed the ability of BoNT/E to cleave SNAP-23 (Fig. 2); in
contrast, the activity of the toxin was not altered by the protease
inhibitors included in the permeabilization buffer to inhibit a broad
range of other cellular proteolytic enzymes (see "Experimental
Procedures"). Therefore, the unique protease activity of BoNT/E must
be responsible for cleavage of murine SNAP-23 in 3T3-L1 adipocytes.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
Proteolysis of mouse SNAP-23 by BoNT/E
requires Zn2+ and reduction of the interchain disulphide
bond of the toxin. 3T3-L1 adipocytes were permeabilized in
digitonin-KGEP buffer at 37 °C for 30 min in the absence or presence
of 100 nM of either prereduced (red) or
nonreduced (non-red) BoNT/E. The reduced toxin was
preincubated with the chelator specified (1,10-phenanthroline
(PTL), 2 mM; EDTA, 2.5 mM; or
dipicolinic acid (DPA), 2 mM) for 30 min at
37 °C in digitonin-KGEP buffer (lacking 2 mM
MgCl2) prior to application to the cells. Equal amounts of
membrane protein were immunoblotted using an antiserum specific for the
C terminus of SNAP-23 as described under "Experimental
Procedures."
|
|
Murine SNAP-23 Is Not as Efficiently Proteolyzed as SNAP-25 by
BoNT/E--
Digitonin-permeabilized chromaffin cells that express
SNAP-25 and 3T3-L1 adipocytes that contain SNAP-23 were exposed to
various concentrations of BoNT/E. The extents of proteolysis of the
respective targets were determined essentially as described in the
legend to Fig. 1, by densitometic scanning of the resultant Western
blots. The concentrations of BoNT/E extrapolated from the plot in Fig. 3 (circles) required to cleave
50% of SNAP-25 was 0.3 nM; in contrast, this extent of
cleavage of murine SNAP-23 in permeabilized adipocytes required 30 nM BoNT/E (Fig. 3, squares). Thus, BoNT/E is
100-fold less effective in cleaving murine SNAP-23 than its homologue, SNAP-25. Nevertheless, BoNT/E could diminish the SNAP-23 content by
90.3 ± 2.8% (mean ± S.D., n = 3). While
2.4 nM BoNT/C1 was sufficient to proteolyze 50% of
SNAP-25, longer term treatment of permeabilized adipocytes with high
concentrations of this toxin (300 nM) caused insignificant
proteolysis of murine SNAP-23 (Fig. 3). A small reduction
(approximately 20%) in murine SNAP-23 by BoNT/A (280 nM)
was observed (Fig. 3); however, because 0.04 nM of BoNT/A
gave an equivalent degree of proteolysis of SNAP-25, cleavage of
SNAP-23 requires approximately 7000 times more toxin. Thus, the ability
of BoNT/E to selectively proteolyze SNAP-23, as well as the incubation
conditions necessary to attain its efficient cleavage, have been
established.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Relative susceptibilities of SNAP-25 and
murine SNAP-23 to BoNTs. Prereduced BoNT/E, BoNT/A, or BoNT/C were
incubated in digitonin-KGEP buffer for 45 min at 37 °C with either
bovine chromaffin cells (source of SNAP-25; circles) or
murine 3T3-L1 fibroblasts (containing SNAP-23; squares).
After terminating the proteolytic activity of the toxins using divalent
cation chelators, post-nuclear membrane fractions were harvested. Equal
amounts of membrane protein were subjected to immunoblotting using the
appropriate antibodies, and the relative amounts of primary antibody
bound were visualized using methods specified in the legend to Fig. 1.
The amount of substrates remaining after BoNT treatments were
quantified by densitometry and expressed as means (± S.D.;
n = 3-5) relative to toxin-free control
incubations.
|
|
To conclude, our observations confirm the reported proteolysis of
bacterially expressed murine SNAP-23 by native BoNT/E (52), although
another group found murine recombinant SNAP-23 to be resistant to the
toxin (25). The inability of this toxin to proteolyze human SNAP-23
agrees with the finding of others (53). SNAP-23, while being 59%
identical in amino acid sequence to SNAP-25, exhibits extensive
diversity at its C terminus (36-38), the region which encompasses the
cleavage sites of BoNT/A, BoNT/C1, and BoNT/E. Thus only small changes
in amino acid sequence between SNAP-25 and human SNAP-23 could account
for the inabilities of BoNT/A, BoNT/C1, or BoNT/E to proteolyze the
latter. Similarly, human and murine forms of SNAP-23 also differ by
13% (36-38), perhaps explaining their differing proteolytic
susceptibilities to BoNTs.
GFP-GLUT4 Trafficking to the Plasma Membrane Occurs in Response to
a Constitutively Active Form of PKB--
Having demonstrated the
cleavage of SNAP-23 by BoNT/E, its effect on GLUT4 translocation was
investigated after microinjection into 3T3-L1 adipocytes. To monitor
GLUT4 translocation, we used a single cell assay that involved
expression of a chimera linking GLUT4 to the C terminus of GFP from the
jellyfish, Aequoria victoria (44). This entailed
microinjecting a plasmid encoding GFP-GLUT4 into the nucleus, followed
by laser scanning confocal microscopy 24 h later. We confirmed
that the GFP-GLUT4 chimera was expressed in native GLUT4-containing
vesicles, by demonstrating its efficient co-localization with
endogenous IRAP, a bona fide GLUT4 vesicle-resident protein
(54, 55). As shown in Fig. 4a,
the majority of the GFP-GLUT4-containing vesicles co-localized with
IRAP. In addition, GFP-GLUT4 was found in GLUT1-containing vesicles
(presumably endosomes) but also in a population of vesicles that
largely lacked GLUT1 (Fig. 4b). This is consistent with the
known apparent distribution of GLUT4 between endosomes and specialized
GLUT4-containing vesicles as determined previously (56, 57). In the
basal state, the bulk of the GFP-tagged GLUT4 was distributed
throughout the cytoplasm and just beneath the plasma membrane but was
also concentrated close to the nucleus (Fig.
5a). Exposure to insulin
resulted in a dramatic redistribution of GFP-GLUT4, such that a
continuous line of fluorescence was observed on the plasma membrane
(Fig. 5b; see also Ref. 44).

View larger version (99K):
[in this window]
[in a new window]
|
Fig. 4.
GFP-tagged GLUT4, IRAP, and GLUT1
co-localization in 3T3-L1 adipocytes. a, 3T3-L1
adipocytes were microinjected with plasmid encoding GFP-GLUT4 and
imaged 24 h later after fixing and staining with an anti-IRAP
antibody, which was detected using TRITC-conjugated anti-rabbit IgG.
b, adipocytes were microinjected with the plasmid encoding
GFP-GLUT4 and imaged 24 h later after fixing and staining with an
anti-GLUT1 antibody that was detected using TRITC-conjugated
anti-rabbit IgG. The figure shows representative laser scanning
confocal micrographs of the distribution of these proteins.
|
|

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 5.
Insulin and constitutively active PKB promote
GFP-GLUT4 translocation. 3T3-L1 adipocytes were microinjected with
a plasmid encoding GFP-GLUT4 and imaged 24 h later after
incubation in the absence (a and c-f) or
presence (b) of 200 nM insulin for 1 h.
Alternatively, the cells were additionally co-microinjected with
plasmids directing the overexpression of wild-type PKB (c
and e) or constitutively active PKB-DD (d and
f). These cells were fixed and, in the case of c
and d, stained with anti-HA antibodies that recognize the
HA-tag on the expressed PKBs. Visualization of GFP-GLUT4 fluorescence
(a, b, e, and f) or anti-HA
immunofluorescence using TRITC (c and d) were
performed by laser scanning confocal microscopy. Selected
representative cells are shown.
|
|
Adipocytes were also co-microinjected with pGFP-GLUT4 and plasmids
encoding either wild-type PKB or a mutant PKB rendered constitutively
active through substitution of Thr308 and
Ser473 for aspartate residues (PKB-DD; both PKB constructs
possessed a HA epitope tag for subsequent detection). The cells were
fixed, stained with anti-HA antibodies, and imaged 24 h
post-microinjection. Interestingly, both wild-type PKB and PKB-DD were
located largely on the plasma membrane (Fig. 5, c and
d); this is different from the predominantly cytosolic
distribution of this kinase in nonstimulated fibroblasts and adipocytes
as determined by either immunofluorescence staining or cell extraction
followed by subcellular fractionation (9, 58-60). The reasons for the
discrepancy are not known but could reflect the ability of the
pleckstrin homology domain of PKB to bind phosphatidylinositide
(4,5)-bisphosphate (61), which may be more abundant in the plasma
membrane of resting 3T3-L1 adipocytes. Nevertheless, a plasma membrane
location of the wild-type protein per se is not sufficient
to promote the translocation of GLUT4-containing vesicles (Fig.
5e). PKB-DD, but not wild-type PKB, caused GFP-GLUT4
translocation to the plasma membrane to a similar extent to that
induced by insulin (i.e. compare Fig. 5, f versus
b). Thus, PKB activation mimicked by substitution of
Thr308 and Ser473 for aspartate residues can
promote GLUT4 translocation.
BoNT/B and /E Block GLUT4 Translocation
Induced by Constitutively Active PKB More Efficiently than That Evoked
by Insulin--
Because 100 nM BoNT/E was required to
cause approximately 90% proteolysis of SNAP-23 in permeabilized 3T3-L1
adipocytes in a 45-min incubation (Fig. 3), concentrations of between
100 and 200 nM were delivered by microinjection. Because
BoNTs can exert their activities over long periods in mammalian cells
(reviewed in Refs. 21 and
30),2 most of the SNAP-23
would be cleaved by type E during the following 24 h period, while
the GFP-GLUT4 was expressed from the co-injected GFP-GLUT4 plasmid. In
validation of this approach, a previous study found that
insulin-stimulated glucose-uptake in BoNT/B-treated 3T3-L1 adipocytes
remains maximally inhibited for at least 48 h (21). Subsequently,
the effect of the toxin on GFP-GLUT4 translocation induced by PKB-DD or
insulin was examined. In parallel experiments, the involvement of
Sbr-2/Cbr was investigated after administration of BoNT/B at a
concentration known in these cells to cause near complete proteolysis
of Sbr-2 and Cbr. At the end of the experiments, the cells were fixed
and stained with anti-HA antibody to confirm, where necessary, the
expression and subcellular location of PKB variants.
The translocation of GFP-tagged GLUT4 was quantified in two ways.
First, we visually examined each cell and determined whether they
exhibited a continuous ring of fluorescence around the plasma membrane,
indicative of translocation. On this basis, in the basal state, none of
the cells showed a "translocated phenotype" (Fig. 6a). It was found that insulin
and PKB-DD induced GFP-GLUT4 translocation in a similar fraction of the
cells (Fig. 6a). (The reason underlying the heterogeneity in
the insulin response is not known but has been noted in our previous
studies on both insulin-stimulated GLUT4 translocation (44) and gene
transcription (62), as well as by all others using the plasma membrane
lawn technique to assess GLUT4 translocation.) As a second measure of
the extent of GFP-GLUT4 translocation, the amount of GFP-GLUT4 found at
the plasma membrane was calculated as a fraction of the total cellular
GFP-GLUT4 measured. Thus, insulin and PKB-DD also caused a similar
increase (approximately 4-fold) in the level of plasma membrane
GFP-GLUT4.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 6.
BoNT/B and BoNT/E block GFP-GLUT4
translocation in 3T3-L1 adipocytes. 3T3-L1 adipocytes were
microinjected with pGFP-GLUT4 and where appropriate PKB-DD, in the
presence of prereduced BoNT/B (B) or BoNT/E (E)
or toxin-free buffer ( ) as indicated. The cells were serum starved
for 2 h and treated, as indicated, in the absence or presence of
200 nM insulin for 1 h. The cells were fixed,
permeabilized, and stained with anti-HA antibodies to confirm the
expression and location of HA-tagged PKB-DD. The cells were then
examined both visually and by laser scanning confocal microscopy. In
a, cells that were deemed visually to have undergone a
translocation response (i.e. exhibited a continuous line of
GFP fluorescence around the plasma membrane) are expressed as the
percentage of all cells examined. In b the data (means ± S.E.) is plotted as the fraction of total GFP-GLUT4 fluorescence
found in the plasma membrane, calculated from a confocal image of the
cell (see "Experimental Procedures"). Because fewer than 50% of
the cells responded to PKB-DD or insulin (a), in
b only those cells that exhibited a translocation response
were used in the quantitation in conditions 2, 5, 6, and 7. In both
panels, the results are pooled from two independent experiments, and
each bar comprises data from 20-44 cells. * indicates p
values of <0.001 versus toxin-free insulin-stimulated
controls.
|
|
The ability of PKB-DD to promote GLUT4 translocation to the plasma
membrane in toxin-free cells (Figs. 6b and 7a)
was completely blocked in the presence of microinjected BoNT/B (Figs.
6b and 7b) or BoNT/E (Figs. 6b and
7c), whereas the expressed PKB-DD was again mostly confined
to the plasma membrane (Fig. 7,
d-f). In the case of insulin, although neither toxin
appeared to reduce the proportion of cells that responded to insulin
(Fig. 6a), the fraction of GFP-GLUT4 that translocated in
each individual cell was reduced by approximately 65% by either toxin
(Fig. 6b). This partial inhibition of the insulin-stimulated
GLUT4 translocation event by BoNT/B is consistent, therefore, with our
previous studies (21). Similarly, Rea et al. (42) reported
that a C-terminal peptide from SNAP-23 or specific antibodies reactive
to the latter only blocked insulin-stimulated GLUT4 translocation by
approximately 40% in permeabilized cells (see "Discussion").

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 7.
BoNT/B and BoNT/E block GFP-GLUT4
translocation in response to constitutively active PKB. 3T3-L1
adipocytes were microinjected with plasmids encoding GFP-GLUT4 and
constitutively active PKB-DD (a-f), in the absence
(a and d) or presence of prereduced BoNT/B
(b and e) or BoNT/E (c and
f). After 24 h, the cells were fixed and immunostained
with anti-HA antibodies to visualize the expressed PKB-DD. The figure
shows fluorescence micrographs obtained by confocal microscopy.
GFP-GLUT4 distribution is visualized in a-c.
d-f illustrate the distribution of PKB detected using
HA-staining.
|
|
Insulin, but Not PKB-DD, Stimulates the Translocation of the
Transferrin Receptor and GLUT1--
The data presented above suggest
that insulin stimulates GLUT4 translocation via two distinct
pathways, only one of which is blocked by BoNT/B or BoNT/E. The latter
may represent the trafficking pathway that responds to the introduction
of the constitutively active PKB-DD mutant. We thus investigated the
nature of the toxin-insensitive GLUT4 trafficking pathway.
In the basal state, GLUT4 is found in a vesicle compartment termed a
GLUT4 storage vesicle (43), which contains Sbr-2 but is apparently
devoid of GLUT1 and the TfR, as well as in the recycling endosomal pool
that also contains the TfR and GLUT1 (Refs. 23, 56, and 57; see also
"Discussion"). Therefore, we investigated the effect of insulin or
PKB-DD on GLUT1 and TfR translocation. Immunofluorescence staining
showed that the majority of cells exhibited relatively low levels of
endogenous GLUT1 on the plasma membrane in the basal state,
i.e. few cells exhibited a continuous ring of
GLUT1 immunofluorescence in the plasma membrane (Figs. 8a and
9a). Insulin treatment caused
an increase in GLUT1 translocation such that approximately 70% of the
cells exhibited a continuous ring of GLUT1 immunoreactivity at the
plasma membrane (Figs. 8b and 9a). Conversely,
expression of the constitutively active PKB-DD had no apparent effect
on the subcellular distribution of GLUT1 or the ability of insulin to
cause a translocation to the plasma membrane (Figs. 8, c and
d, and 9a). The extent of GLUT1 translocation was
quantified and expressed as the fraction of cellular GLUT1 present in
the plasma membrane (% of total). In cells expressing wild-type PKB,
8.9 ± 0.9% (n = 46) of the GLUT1 was expressed in the plasma membrane (mean ± S.E. for the number of cells shown in parentheses and pooled from three independent experiments). In the
presence of PKB-DD but the absence of insulin, 6.2 ± 0.6% (n = 41) of the GLUT1 was found in the plasma membrane;
however, this increased to 22.1 ± 1.7% (n = 37)
in the simultaneous presence of insulin and PKB-DD (p < 0.001 versus control without insulin).

View larger version (91K):
[in this window]
[in a new window]
|
Fig. 8.
GLUT1 and transferrin receptor translocation
are stimulated by insulin but not by PKB-DD. 3T3-L1 adipocytes
were microinjected in the absence or presence of plasmids encoding the
human transferrin receptor (e-h) and PKB-DD (c,
d, g, and h). 24 h later the
cells were incubated in the absence (a, c,
d, e, g, and h) or presence
(b and f) of 200 nM insulin for
1 h prior to fixation and staining with polyclonal anti-GLUT1
antibodies (a-c) or murine monoclonal anti-hTfR antibodies
(e-g). The cells in c and g were
co-stained with rabbit polyclonal antibodies reactive with the HA
epitope present on the expressed PKB to give d and
h, respectively. Visualization of GLUT1 and transferrin
receptors (with TRITC) or PKB-DD (using fluorescein isothiocyanate) was
performed by laser scanning confocal microscopy. Selected
representative cells are shown.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 9.
Insulin, but not PKB-DD, stimulates GLUT1 and
transferrin receptor translocation to the plasma membrane of 3T3-L1
adipocytes, responses that are resistant to the action of BoNTs.
In a, 3T3-L1 adipocytes were microinjected with or without
pCMV5·hTfR where appropriate and in the absence or presence of PKB-DD
as indicated. After 24 h the cells were serum starved for 2 h
and treated in the absence or presence of 200 nM insulin
for 1 h, as specified. The cells were fixed, permeabilized and,
where specified, stained with anti-GLUT1 or anti-hTfR antibodies. The
cells were then examined both visually and by laser scanning confocal
microscopy. Those that exhibited a continuous line of GLUT1- or
transferrin receptor-derived fluorescence around the plasma membrane
were deemed to have undergone translocation. These data are expressed
as the percentages of cells examined that underwent translocation. Each
bar comprises at least 65 cells pooled from at least two separate
experiments. In b, 3T3-L1 adipocytes were microinjected with
pCMV5·hTfR and, where indicated, with prereduced BoNT/B or BoNT/E or
toxin-free buffer ( ). The cells were treated in the absence or
presence of insulin and were then fixed, permeabilized, and stained
with anti-hTfR antibodies. All the cells expressing hTfR were then
examined by laser scanning confocal microscopy, and the amount of hTfR
located in the plasma membrane was calculated as a fraction of the
total cellular content. The data are expressed as means ± S.E.
Each bar represents data from at least 150 cells, pooled
from at least two separate experiments. # indicates
p values <0.001 versus toxin-free basal
controls. * indicates that no significant statistical difference exists
relative to insulin-treated toxin-free controls.
|
|
To investigate the distribution of the TfR and because our antisera do
not detect endogenous murine TfR, 3T3-L1 adipocytes were microinjected
with a plasmid encoding the hTfR. This was subsequently detected by
immunofluorescence staining with a highly avid monoclonal antibody
specific for the human form of the receptor. In the basal state, the
expressed hTfR was predominantly located intracellularly (Fig.
8e) and exhibited a considerable co-localization with
endogenous GLUT4 (data not shown), although this was incomplete, as
would be expected (57). Unlike GLUT1, however, in some cells (approximately 20-30%; Fig. 9b) a continuous ring of hTfR
immunofluorescence was found in the plasma membrane probably as a
result of overexpression. Exposure to insulin caused a pronounced
translocation of hTfR to the plasma membrane such that approximately
70% of the cells now exhibited a continuous ring of hTfR around the
plasma membrane (Figs. 8f and 9a). But, as with
GLUT1, the constitutively active PKB-DD mutant did not promote any
detectable translocation of hTfR to the plasma membrane or alter the
ability of insulin to cause translocation of the latter (Figs.
8g and 9a).
The effects of BoNT/B and BoNT/E on insulin-stimulated transferrin
receptor translocation were quantified; the ectopic expression of the
hTfR allowed us to easily detect the toxin injected cells. However,
neither BoNT had any significant effect on insulin-stimulated translocation of hTfR (Fig. 9b). In support of the validity
of our results, a recent study by Martin and co-workers (23) found that
transferrin-horseradish peroxidase-mediated ablation of recycling TfR-containing endosomes inhibited the subsequent insulin-stimulated translocations of TfR, as well as GLUT1. Despite this, insulin was
still able to elicit large increases in the cell surface levels of
GLUT4, presumably through activation of an alternate vesicle trafficking pathway (i.e. distinct from the fusion of
recycling endosomes with the plasma membrane).
 |
DISCUSSION |
The molecular basis underlying the ability of insulin to promote
the translocation of GLUT4 and thus stimulate glucose uptake remains
incompletely defined. Our results comparing the effects of insulin and
a constitutively active PKB mutant, together with the use of two
botulinum toxins, support the proposal (16, 23, 42, 43, 57) that at
least two pathways are involved in insulin-stimulated GLUT4 trafficking
to the plasma membrane. Notably, our results suggest that only one of
these pathways is sensitive to the action of a constitutively active
PKB.
Insulin stimulated the translocation of GLUT1, GLUT4, and the TfR to
the plasma membrane of 3T3-L1 adipocytes. This contrasted with the
effect of overexpressing a constitutively active PKB-DD mutant
(rendered active via substitution of the PDK1 and PDK2 phosphorylation sites with aspartate residues), which promoted only a
translocation of GLUT4 but not GLUT1 or TfR. The effect of PKB-DD on
GLUT4 translocation is consistent with the known effects on glucose
transport of the constitutively active gag-Akt oncogene and a PKB
mutant possessing a myristoylation signal sequence at its N terminus
(8, 9). Although this suggests that PKB activation can mimic
insulin-stimulated GLUT4 translocation, its precise role in the effect
of insulin remains controversial. For example, Cong and co-workers (63)
found that a dominant-negative PKB blocked insulin-stimulated glucose
transport by approximately 20%, whereas Kitamura et al.
(64) found no apparent effect. Regardless of this controversy,
constitutively active PKB-DD is clearly a useful tool to investigate
the mechanism by which insulin may promote GLUT4 translocation.
We investigated the role of SNARE proteins in the insulin- and
PKB-mediated translocations of GLUT4, GLUT1, or TfR. Numerous studies
have highlighted the essential requirement of syntaxin 4 and Sbr-2/Cbr
for insulin-stimulated GLUT4 vesicle translocation in adipocytes (see
the Introduction). To form a high affinity interaction between
vesicle-derived Sbr and plasma membrane syntaxin-1, SNAP-25 is required
(39, 40). However, numerous laboratories (20, 25, 34, 35, 38),
including our own (see the Introduction) have been unable to detect the
expression of SNAP-25 in 3T3-L1 adipocytes, despite the use of
extremely sensitive Western blotting and high affinity selective
antibodies. This prompted us to investigate the role of SNAP-23, which
exhibits the appropriate molecular characteristics (see the
Introduction), is abundant in 3T3-L1 adipocytes and was reported by
James and colleagues (42) to be involved in insulin-stimulated glucose uptake.
BoNT/E cleaves murine, but not human, SNAP-23 in permeabilized cells,
albeit at 100-fold higher concentrations than required for equivalent
cleavage of SNAP-25. However, when employed at a sufficient
concentration, BoNT/E can proteolyze >90% of SNAP-23, thus enabling
an assessment of the role of this SNARE in GLUT4 vesicle trafficking.
To do this, we microinjected BoNT/B or BoNT/E and performed single cell
imaging of GLUT4 translocation using a GFP-tagged GLUT4 construct.
Although insulin-stimulated GLUT4 translocation to the plasma membrane
was partially blocked (approximately 65%) by BoNT/E, intriguingly this
toxin completely blocked the effect of PKB-DD on GLUT4 translocation
(Figs. 6 and 7). The same result was obtained following introduction of
BoNT/B into cells to cleave the Sbr-2/Cbr present. Collectively, these
observations suggest that PKB-dependent GFP-GLUT4
translocation is completely dependent on Sbr-2/Cbr and SNAP-23.
Although a variety of methods have been used to interfere with SNARE
interactions in adipocytes, only partial inhibitions (maximally between
65-80%) of insulin-stimulated glucose uptake and GLUT4 translocation
have been reported. These include the use of botulinum or tetanus
toxins (21, 24, 26), interfering SNARE fragments, and peptides (14, 16,
22, 42) or inhibitory anti-SNARE antibodies (14, 42). Failure to
achieve a complete blockade of the insulin response thus led to the
proposal that insulin uses both BoNT-sensitive and -insensitive
pathways to promote GLUT4 translocation. Our data suggest that PKB-DD
exclusively stimulates GLUT4 translocation via the BoNT-sensitive
pathway and from a vesicle pool that lacks GLUT1 and TfR. Such a
vesicle population probably represents the post-endocytic GLUT4 storage compartment termed GLUT4 storage vesicles by Rea and James (43) and
that resembles small synaptic vesicles with respect to its SNARE
content and recycling characteristics.
Although GLUT4 and GLUT1 have been shown to segregate into distinct
vesicle pools in adipocytes (56, 56, 66), there is also considerable
evidence to suggest that a substantial fraction of GLUT4 (approximately
40-50% (56, 57)) also resides in recycling endosomes that contain
GLUT1 and the TfR. Insulin-stimulated translocation of GLUT1 from this
latter pool to the plasma membrane occurs independently of Sbr-2/Cbr
and SNAP-23 (16, 23, 42), observations that are consistent with our own
data in which neither BoNT/B nor BoNT/E blocked insulin-stimulated TfR
translocation (Fig. 9b). It is curious to note that despite
the known presence of Cbr in approximately 60% of transferrin
receptor-containing vesicles in 3T3-L1 adipocytes (57), we observe no
significant inhibition of insulin-stimulated translocation when Cbr
function is prevented. Although an earlier study (21) suggested that
Cbr may mediate insulin-stimulated GLUT4 translocation, more recently
Martin and co-workers (23) found that only Sbr-2 was likely to be
involved. Therefore, the precise function of Cbr in 3T3-L1 adipocytes
is yet to be defined.
Although the exocytosis of GLUT1- and TfR-containing vesicles recycling
via the endocytic pathway is not sensitive to the actions of PKB-DD
(Fig. 8), inhibitors of PI3-kinase have been reported to block
insulin-stimulated translocation of the transferrin receptor (67) and
GLUT1 (4). Taken together with our own data, this suggests that
PI3-kinase is central to the translocation of GLUT4 from both pools.
However, the signal may then diverge such that PKB then mobilizes GLUT4
to the plasma membrane from the GLUT4 storage vesicles and an as yet
unknown pathway stimulates mobilization of GLUT4, GLUT1, and the TfR
from recycling endosomes. If the two pools of GLUT4 are in dynamic
equilibrium, in the presence of dominant-negative PKB, GLUT4 may be
able to traffic to the plasma membrane by returning into recycling
endosomes. The extent to which insulin utilizes these two trafficking
mechanisms in any one cell type and the degree to which these pools
might equilibrate may help to explain why dominant-negative PKBs only
partially suppress insulin-stimulated GLUT4 translocation (63), if they have any effect at all (64). This possibility requires further investigation.
Concluding Comments--
Our data lend support to the proposal
that GLUT4 translocation occurs via at least two distinct trafficking
pathways. One is Sbr-2/Cbr and SNAP-23-dependent and may
represent GLUT4 storage vesicles that can be mobilized to the plasma
membrane in response to constitutively active PKB-DD. This pathway may
correspond to the pool of GLUT4 in adipocytes reported to resemble
small synaptic vesicles in neurons (based on morphology and recycling
characteristics). The other trafficking pathway is Sbr-2/Cbr- and
SNAP-23-independent (or can at least use alternative
BoNT-insensitive SNARE proteins) and is not stimulated by PKB-DD.
The latter pathway may represent the translocation of GLUT4 present in
GLUT1- or TfR-containing endosomes.
Other trafficking pathways and/or signaling mechanisms may also exist.
For example, GLUT4 translocation induced by osmotic shock or GTP
S in
adipocytes or contraction in muscle have been reported to occur
independently of PI3-kinase and protein kinase B (22, 65, 68, 69).
Clearly, identifying the events between PI3-kinase activation and
SNARE-dependent docking/fusion of GLUT4 vesicles, as well
as the other "putative" pathways utilized by insulin that may
operate independently of Sbr-2/Cbr and SNAP-23, are important avenues
for future exploration.
 |
ACKNOWLEDGEMENTS |
We are grateful to Gwyn Gould and Geoff
Holman for many useful discussions, Clifford Shone and Bibhuti DasGupta
for the kind provision of some of the neurotoxins used in this study,
Susanna Keller and Gus Lienhard for the anti-IRAP antibodies, and Brian Hemmings and Dario Alessi for the PKB constructs. Mark Bennett and
Richard Scheller are thanked for generous gifts of antiserum reactive
with syntaxin 4. The provision of cultured chromaffin cells by Gregory
O'Sullivan and Gary Lawrence is much appreciated, as are the samples
of CACO-2 cells and plasmid preparations by Radhika Prathalingam and
Jackie Webb.
 |
FOOTNOTES |
*
This work was supported by grants from the Medical Research
Council and the British Diabetic Association (to J. M. T.)
and by Contract DAMD 17-97-C-7060 from the United States Army Medical Research and Material Command (to J. O. D.). The confocal
microscopy was performed using the Bristol Cell Imaging Facility that
was funded by an Infrastructure Grant from the Medical Research
Council.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
British Diabetic Association Senior Research Fellow. To whom
correspondence should be addressed. Tel.: 44-117-928-8273; Fax: 44-117-928-8274; E-mail, j.tavare@bristol.ac.uk.
2
P. G. P. Foran, L. M. Fletcher,
P. B. Oatey, N. Mohammed, J. O. Dolly, and J. M. Tavaré, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
PI3-kinase, phosphatidylinositide (4,5)-bisphosphate kinase;
BoNT, botulinum
neurotoxin;
Cbr, cellubrevin;
GFP, green-fluorescent protein;
IRAP, insulin-responsive amino peptidase;
TfR, transferrin receptor;
hTfR, human TfR;
HA, hemagglutinin;
PKB, protein kinase B;
Sbr, synaptobrevin;
TeTx, tetanus toxin;
TRITC, tetramethylrhodamine
-isothiocyanate;
GTP
S, guanosine
5'-3-O-(thio)triphosphate;
PIPES, 1,4-piperazinediethanesulfonic acid.
 |
REFERENCES |
| 1.
|
Holman, G. D.,
and Kasuga, M.
(1997)
Diabetologia
40,
991-1003[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Kandror, K. V.,
and Pilch, P. F.
(1996)
Am. J. Physiol. Endocrinol. Metab.
34,
E1-E14
|
| 3.
|
Yenush, L.,
and White, M. F.
(1997)
Bioessays
19,
491-500[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Clarke, J. F.,
Young, P. W.,
Yonezawa, K.,
Kasuga, M.,
and Holman, G. D.
(1994)
Biochem. J.
300,
631-635
|
| 5.
|
Tanti, J. F.,
Gremeaux, T.,
Grillo, S.,
Calleja, V.,
Klippel, A.,
Williams, L. T.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1996)
J. Biol. Chem.
271,
25227-25232[Abstract/Free Full Text]
|
| 6.
|
Martin, S. S.,
Haruta, T.,
Morris, A. J.,
Klippel, A.,
Williams, L. T.,
and Olefsky, J. M.
(1996)
J. Biol. Chem.
271,
17605-17608[Abstract/Free Full Text]
|
| 7.
|
Alessi, D. R.,
and Cohen, P.
(1998)
Curr. Opin. Genet. Dev.
8,
55-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Kohn, A. D.,
Summers, S. A.,
Birnbaum, M. J.,
and Roth, R. A.
(1996)
J. Biol. Chem.
271,
31372-31378[Abstract/Free Full Text]
|
| 9.
|
Tanti, F.,
Grillo, S.,
Gremeaux, T.,
Coffer, P. J.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1997)
Endocrinology
138,
2005-2010[Abstract/Free Full Text]
|
| 10.
|
Söllner, T.
(1995)
FEBS Lett.
369,
80-83[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Söllner, T.,
Whiteheart, S. W.,
Brunner, M.,
Erdjument-Bromage, H.,
Geromanos, S.,
Tempst, P.,
and Rothman, J.
(1993)
Nature
362,
318-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
McMahon, H. T.,
Ushkaryov, Y. A.,
Edelmann, L.,
Link, E.,
Binz, T.,
Niemann, H.,
Jahn, R.,
and Sudhof, T. C.
(1993)
Nature
364,
346-349[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Bennett, M. K.,
Garcia-Arraras, J. E.,
Elferink, L. A.,
Peterson, K.,
Fleming, A. M.,
Hazuka, C. D.,
and Scheller, R. H.
(1993)
Cell
74,
863-873[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Volchuk, A.,
Wang, Q. H.,
Ewart, H. S.,
Liu, Z.,
He, L. J.,
Bennett, M. K.,
and Klip, A.
(1996)
Mol. Biol. Cell
7,
1075-1082[Abstract]
|
| 15.
|
Cain, C. C.,
Trimble, W. S.,
and Lienhard, G. E.
(1992)
J. Biol. Chem.
267,
11681-11684[Abstract/Free Full Text]
|
| 16.
|
Olson, A. L.,
Knight, J. B.,
and Pessin, J. E.
(1997)
Mol. Cell. Biol.
17,
2425-2435[Abstract]
|
| 17.
|
Volchuk, A.,
Sargeant, R.,
Sumitani, S.,
Liu, Z.,
He, L.,
and Klip, A.
(1995)
J. Biol. Chem.
270,
8233-8240[Abstract/Free Full Text]
|
| 18.
|
Jagadish, M. N.,
Fernandez, O. S.,
Hewish, D. R.,
Macaulay, S. L.,
Gough, K. H.,
Grusovin, J.,
Verkuylen, A.,
Cosgrove, L.,
Alafaci, A.,
Frenkel, M. J.,
and Ward, C. J.
(1996)
Biochem. J.
317,
945-954
|
| 19.
|
Jagadish, M. N.,
Tellam, J. D.,
Macaulay, S. L.,
Gough, K. H.,
James, D. E.,
and Ward, C. W.
(1997)
Biochem. J.
321,
151-156
|
| 20.
|
Timmers, K. I.,
Clark, A. E.,
Omatsu-Kanbe, M.,
Whiteheart, S. W.,
Bennett, M. K.,
Holman, G. D.,
and Cushman, S. W.
(1996)
Biochem. J.
320,
429-436
|
| 21.
|
Chen, F.,
Foran, P.,
Shone, C. C.,
Foster, K. A.,
and Dolly, J. O.
(1997)
Biochemistry
36,
5719-5728[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Chen, D.,
Elmendorf, J. S.,
Olson, A. L.,
Li, X.,
Earp, S.,
and Pessin, J. E.
(1997)
J. Biol. Chem.
272,
27401-27410[Abstract/Free Full Text]
|
| 23.
|
Martin, L. B.,
Shewan, A.,
Millar, C. A.,
Gould, G. W.,
and James, D. E.
(1998)
J. Biol. Chem.
273,
1444-1452[Abstract/Free Full Text]
|
| 24.
|
Cheatham, B.,
Volchuk, A.,
Kahn, C. R.,
Wang, L.,
Rhodes, C. J.,
and Klip, A.
(1996)
Proc. Natl Acad. Sci. U. S. A.
93,
15169-15173[Abstract/Free Full Text]
|
| 25.
|
Macaulay, S. L.,
Rea, S.,
Gough, K. H.,
Ward, C. W.,
and James, D. E.
(1997)
Biochem. Biophys Res. Commun.
237,
388-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Tamori, Y.,
Hashiramoto, M.,
Araki, S.,
Kamata, Y.,
Takahashi, M.,
Kozaki, S.,
and Kasuga, M.
(1996)
Biochem. Biophys. Res. Commun.
220,
740-745[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Simpson, L. L.
(1986)
Infect. Immun.
52,
858-862[Abstract/Free Full Text]
|
| 28.
|
Montecucco, C.,
and Schiavo, G.
(1993)
Trends Biochem. Sci.
18,
324-327[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Niemann, H.,
Blasi, J.,
and Jahn, R.
(1994)
Trends Cell Biol.
4,
179-185[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Dolly, J. O.
(1992)
in
in Handbook of Experimental Pharmacology: Selective Neurotoxicity
(Herken, H.
, and Hucho, F., eds), Vol. 102
, pp. 681-717, Springer-Verlag, Berlin
|
| 31.
|
Foran, P.,
Lawrence, G.,
and Dolly, J. O.
(1995)
Biochemistry
34,
5494-5503[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Foran, P.,
Lawrence, G. W.,
Shone, C. C.,
Foster, K.,
and Dolly, J. O.
(1996)
Biochemistry
35,
2630-2636[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Williamson, L. C.,
Halpern, J. L.,
Montecucco, C.,
Brown, J. E.,
and Neale, E. A.
(1996)
J. Biol. Chem.
271,
7694-7699[Abstract/Free Full Text]
|
| 34.
|
Wong, P. P. C.,
Daneman, N.,
Volchuk, A.,
Lassam, N.,
Wilson, M. C.,
Klip, A.,
and Trimble, W. S.
(1997)
Biochem. Biophys. Res. Commun.
230,
64-68[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Macaulay, S. L.,
Hewish, D. R.,
Gough, K. H.,
Stoichevska, V.,
MacPherson, S. F.,
Jagadish, M.,
and Ward, C. W.
(1997)
Biochem. J.
324,
217-224
|
| 36.
|
Ravichandran, V.,
Chawla, A.,
and Roche, P. A.
(1996)
J. Biol. Chem.
271,
13300-13303[Abstract/Free Full Text]
|
| 37.
|
Araki, S.,
Tamori, Y.,
Kawanishi, M.,
Shinoda, H.,
Masugi, J.,
Mori, H.,
Niki, T.,
Okazawa, H.,
Kubbota, T.,
and Kasuga, M.
(1997)
Biochem. Biophys. Res. Commun.
234,
257-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Wang, G.,
Witkin, J. W.,
Hao, G.,
Bankaitis, V. A.,
Scherer, P. E.,
and Baldini, G.
(1997)
J. Cell Sci.
110,
505-513[Abstract]
|
| 39.
|
Pevsner, J.,
Hsu, S.-C.,
Braun, J. E. A.,
Calakos, N.,
Ting, A. E.,
Bennett, M. K.,
and Scheller, R. H.
(1994)
Neuron
13,
353-361[CrossRef][Medline]
[Order article via Infotrieve] |